Download PDF
Der Klinikarzt 2019; 48(08/09): 360-369
DOI: 10.1055/a-0992-7598
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Aphereseverfahren bei Autoimmunerkrankungen

Einsatz in der Primär- und Eskalationstherapie
Sebastian Heibel
1   Medizinische Klinik III (Nephrologie, Dialyse, Hypertensiologie, Rheumatologie), Sana Klinikum Offenbach GmbH, KfH-Nierenzentrum Offenbach, Offenbach a. M.
,
Kirsten de Groot
1   Medizinische Klinik III (Nephrologie, Dialyse, Hypertensiologie, Rheumatologie), Sana Klinikum Offenbach GmbH, KfH-Nierenzentrum Offenbach, Offenbach a. M.
› Author Affiliations
Further Information

Publication History

Publication Date:
19 September 2019 (online)

Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Aphereseverfahren finden neben ihrem etablierten Einsatz in derTransplantations- und Transfusionsmedizin vor allem in der Therapie autoimmunologischer entzündlich-rheumatischer und neurologischer Erkrankungen zunehmende klinische Anwendung. Ihre grundsätzliche Funktionsweise liegt im Entzug pathophysiologisch wirksamer Blutbestandteile (v. a. IgG-Antikörper) und weiteren immunmodulatorischen Effekten. Mögliche Apheresemodalitäten sind die unselektive Plasmapherese mit nachfolgendem Ersatz des entzogenen Plasmas durch verschiedenartige Substituate sowie die selektivere Immunadsorption. Die Therapie ist logistisch aufwendig, jedoch für den Patienten nebenwirkungsarm.

 

  • Literatur

  • 1 Winters JL. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. Hematology Am Soc Hematol Educ Program 2012; 2012: 7-12
    CrossrefPubMedGoogle Scholar
  • 2 Renders L, Wen M, Küchle C. Plasmapherese und Immunadsorption. Der Nephrologe 2014; 9: 284-292
    CrossrefPubMedGoogle Scholar
  • 3 Koessler J, Kobsar A, Kuhn S. et al The effect of immunoadsorption with the Immusorba TR-350 column on coagulation compared to plasma exchange. Vox Sang 2015; 108: 46-51
    CrossrefPubMedGoogle Scholar
  • 4 Orlando G, Remuzzi G, Williams DF. Kidney Transplantation, Bioengineering, and Regeneration: Kidney Transplantation in the Regenerative Medicine Era. Elsevier Science; 2017
    Google Scholar
  • 5 Golestaneh L, Mokrzycki MH. Vascular access in therapeutic apheresis: update, 2013. J Clin Apher 2013; 28: 64-72
    CrossrefPubMedGoogle Scholar
  • 6 Tsuboi Y, Takahashi M, Ishikawa Y. et al Elevated bradykinin and decreased carboxypeptidase R as a cause of hypotension during tryptophan column immunoabsorption therapy. Ther Apher 1998; 2: 297-299
    CrossrefPubMedGoogle Scholar
  • 7 Schwartz J, Padmanabhan A, Aqui N. et al Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher 2016; 31: 149-162
    CrossrefPubMedGoogle Scholar
  • 8 Faissner S, Nikolayczik J, Chan A. et al Immunoadsorption in patients with neuromyelitis optica spectrum disorder. Ther Adv Neurol Disord 2016; 9: 281-286
    CrossrefPubMedGoogle Scholar
  • 9 Schneider-Gold C, Krenzer M, Klinker E. et al Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration. Ther Adv Neurol Disord 2016; 9: 297-303
    CrossrefPubMedGoogle Scholar
  • 10 Lockwood CM, Rees AJ, Pearson TA. et al Immunosuppression and plasma-exchange in the treatment of Goodpasture‘s syndrome. Lancet 1976; 1: 711-715
    PubMedGoogle Scholar
  • 11 Johnson JP, Moore JR J, Austin H. A3 et al Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) 1985; 64: 219-227
    PubMedGoogle Scholar
  • 12 Biesenbach P, Kain R, Derfler K. et al Long-term outcome of anti-glomerular basement membrane antibody disease treated with immunoadsorption. PLoS One 2014; 9: e103568
    CrossrefPubMedGoogle Scholar
  • 13 Jayne DRW, Gaskin G, Rasmussen N. et al Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18: 2180-2188
    CrossrefPubMedGoogle Scholar
  • 14 Walsh M, Casian A, Flossmann O. et al Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 2013; 84: 397-402
    CrossrefPubMedGoogle Scholar
  • 15 Walsh M. Late breaking clinical trials. 55 rd ERA-EDTA CONGRESS COPENHAGEN DENMARK – May 24th–27th, 2018. Daily Congress Newspaper 2018; 3: 1
    PubMedGoogle Scholar
  • 16 Cartin-Ceba R, Diaz-Caballero L, Al-Qadi MO. et al Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes. Arthritis Rheumatol 2016; 68: 1467-1476
    CrossrefPubMedGoogle Scholar
  • 17 Cacoub P, Comarmond C, Domont F. et al Cryoglobulinemia Vasculitis. Am J Med 2015; 128: 950-955
    CrossrefPubMedGoogle Scholar
  • 18 Yu X, Zhang L, Wang L. et al MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial. Clin Rheumatol 2018; 37: 917-925
    CrossrefPubMedGoogle Scholar
  • 19 Kronbichler A, Brezina B, Quintana LF, Jayne DRW. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. Vol. 1. Netherlands: 2016. Jan
    Google Scholar
  • 20 Danieli MG, Palmieri C, Salvi A. et al Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J Clin Apher 2002; 17: 72-77
    CrossrefPubMedGoogle Scholar
  • 21 Stummvoll GH, Schmaldienst S, Smolen JS. et al Lupus nephritis: prolonged immunoadsorption (IAS) reduces proteinuria and stabilizes global disease activity. Nephrol Dial Transplant 2012; 27: 618-626
    CrossrefPubMedGoogle Scholar
  • 22 Yuki N, Susuki K, Koga M. et al Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci U S A 2004; 101: 11404-11409
    CrossrefPubMedGoogle Scholar
  • 23 Stoll G, Reiners K. Immune-mediated neuropathies. Nervenarzt 2016; 87: 887-898
    CrossrefPubMedGoogle Scholar
  • 24 Cortese I, Chaudhry V, So YT. et al Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 76: 294-300
    CrossrefPubMedGoogle Scholar
  • 25 Marn Pernat A, Buturovic-Ponikvar J, Svigelj V. et al Guillain-Barre syndrome treated by membrane plasma exchange and/or immunoadsorption. Ther Apher Dial 2009; 13: 310-313
    CrossrefPubMedGoogle Scholar
  • 26 Fokke C, van den Berg B, Drenthen J. et al Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria. Brain 2014; 137: 33-43
    CrossrefPubMedGoogle Scholar
  • 27 Galldiks N, Burghaus L, Dohmen C. et al Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment. Eur Neurol 2011; 66: 183-189
    CrossrefPubMedGoogle Scholar
  • 28 Lieker I, Slowinski T, Harms L. et al A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy. J Clin Apher 2017; 32: 486-493
    CrossrefPubMedGoogle Scholar
  • 29 Gilhus NE. Myasthenia Gravis. N Engl J Med 2016; 375: 2570-2581
    CrossrefPubMedGoogle Scholar
  • 30 Kohler W, Bucka C, Klingel R. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher 2011; 26: 347-355
    CrossrefPubMedGoogle Scholar
  • 31 Grob D, Simpson D, Mitsumoto H. et al Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 1995; 45: 338-344
    CrossrefPubMedGoogle Scholar
  • 32 Liew WKM, Powell CA, Sloan SR. et al Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol 2014; 71: 575-580
    CrossrefPubMedGoogle Scholar
  • 33 Gajdos P, Chevret S, Clair B. et al Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997; 41: 789-796
    CrossrefPubMedGoogle Scholar
  • 34 Noseworthy JH, Lucchinetti C, Rodriguez M. et al Multiple sclerosis. N Engl J Med 2000; 343: 938-952
    CrossrefPubMedGoogle Scholar
  • 35 Gold R. Diagnose und Therapie der Multiplen Sklerose. In Diener H-C, Weimar C Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme; 2012
    Google Scholar
  • 36 Faissner S, Nikolayczik J, Chan A. et al Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses. J Neurol 2016; 263: 1092-1098
    CrossrefPubMedGoogle Scholar
  • 37 Park-Wyllie L, Mazzotta P, Pastuszak A. et al Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62: 385-392
    CrossrefPubMedGoogle Scholar
  • 38 Hoffmann F, Kraft A, Heigl F. et al Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica. Ther Adv Neurol Disord 2018; 11: 1756286418774973
    CrossrefPubMedGoogle Scholar
  • 39 Cox JL, Koepsell SA, Shunkwiler SM. Therapeutic plasma exchange and pregnancy: A case report and guidelines for performing plasma exchange in a pregnant patient. J Clin Apher 2017; 32: 191-195
    CrossrefPubMedGoogle Scholar
  • 40 Wingerchuk DM, Lennon VA, Lucchinetti CF. et al The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815
    CrossrefPubMedGoogle Scholar
  • 41 Kim S-H, Kim W, Huh S-Y. et al Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol 2013; 9: 36-42
    CrossrefPubMedGoogle Scholar
  • 42 Dalmau J, Tüzün E, Wu H. et al Paraneoplastic Anti-N-methyl-D-aspartate Receptor Encephalitis Associated with Ovarian Teratoma. Ann Neurol 2007; 61: 25-36
    CrossrefPubMedGoogle Scholar